Binding Site Information of Target
| Target General Information | Top | ||||
|---|---|---|---|---|---|
| Target ID | T24793 | Target Info | |||
| Target Name | Voltage-gated calcium channel alpha Cav1.3 (CACNA1D) | ||||
| Synonyms | Voltage-gated calcium channel alpha subunit Cav1.3; Voltage-gated L-type Ca2+ channel alpha1D; Calcium channel, L type, alpha-1 polypeptide, isoform 2; CACNA1D | ||||
| Target Type | Clinical trial Target | ||||
| Gene Name | CACNA1D | ||||
| Biochemical Class | Voltage-gated ion channel | ||||
| UniProt ID | |||||
| Drug Binding Sites of Target | Top | |||||
|---|---|---|---|---|---|---|
| Ligand Name: Cinnarizine | Ligand Info | |||||
| Structure Description | Human L-type voltage-gated calcium channel Cav1.3 in the presence of cinnarizine at 3.1 Angstrom resolution | PDB:7UHF | ||||
| Method | Electron microscopy | Resolution | 3.10 Å | Mutation | No | [1] |
| PDB Sequence |
SIVEWKPFDI
130 FILLAIFANC140 VALAIYIPFP150 EDDSNSTNHN160 LEKVEYAFLI170 IFTVETFLKI 180 IYVRNGWNLL200 DFVIVIVGLF210 SVILEQLTDV236 KALRAFRVLR246 PLRLVSGVPS 256 LQVVLNSIIK266 AMVPLLHIAL276 LVLFVIIIYA286 IIGLELFIGK296 MHKTCFFADS 306 DIVAEEDPAP316 CAFSGNGRQC326 TANGTECRSG336 WVGPNGGITN346 FDNFAFAMLT 356 VFQCITMEGW366 TDVLYWMNDA376 MGFELPWVYF386 VSLVIFGSFF396 VLNLVLGVLS 406 GEFSKEREKA416 KARGDFQKLR426 EKQQLEEDLK436 GYLDWITQAE446 DCRAAVKSVT 524 FYWLVIVLVF534 LNTLTISSEH544 YNQPDWLTQI554 QDIANKVLLA564 LFTCEMLVKM 574 YSLGLQAYFV584 SLFNRFDCFV594 VCGGITETIL604 VELEIMSPLG614 ISVFRCVRLL 624 RIFKVTRHWT634 SLSNLVASLL644 NSMKSIASLL654 LLLFLFIIIF664 SLLGMQLFGG 674 KFNFDETQTK684 RSTFDNFPQA694 LLTVFQILTG704 EDWNAVMYDG714 IMAYGGPSSS 724 GMIVCIYFII734 LFICGNYILL744 NVFLAIAVDN754 LADAESLNTA764 QKEEAEEKIR 876 VGCHKLINHH886 IFTNLILVFI896 MLSSAALAAE906 DPIRSHSFRN916 TILGYFDYAF 926 TAIFTVEILL936 KMTTFGNYFN956 LLDMLVVGVS966 LVSFVVKILR984 VLRVLRPLRA 994 INRAKGLKHV1004 VQCVFVAIRT1014 IGNIMIVTTL1024 LQFMFACIGV1034 QLFKGKFYRC 1044 TDEAKSNPEE1054 CRGLFILYKD1064 GDVDSPVVRE1074 RIWQNSDFNF1084 DNVLSAMMAL 1094 FTVSTFEGWP1104 ALLYKAIDSN1114 GENIGPIYNH1124 RVEISIFFII1134 YIIIVAFFMM 1144 NIFVGFVIVT1154 FQEQGEKEYK1164 NCELDKNQRQ1174 CVEYALKARP1184 LRRYIPKNPY 1194 QYKFWYVVNS1204 SPFEYMMFVL1214 IMLNTLCLAM1224 QHYEQSKMFN1234 DAMDILNMVF 1244 TGVFTVEMVL1254 KVIAFKPKGY1264 FSDAWNTFDS1274 LIVIGSIIDV1284 ALSESITFFR 1319 LFRVMRLVKL1329 LSRGEGIRTL1339 LWTFIKSFQA1349 LPYVALLIAM1359 LFFIYAVIGM 1369 QMFGKVAMRD1379 NNQINRNNNF1389 QTFPQAVLLL1399 FRCATGEAWQ1409 EIMLACLPGK 1419 LCDPESDYNP1429 GEEYTCGSNF1439 AIVYFISFYM1449 LCAFLIINLF1459 VAVIMDNFDY 1469 LTRDWSILGP1479 HHLDEFKRIW1489 SEYDPEAKGR1499 IKHLDVVTLL1509 RRIQPPLGFG 1519 KLCPHRVACK1529 RLVAMNMPLN1539 SDGTVMFNAT1549 LFALVRTALK1559 IKTEGNLEQA 1569 NEELRAVIKK1579 IWKKTSMKLL1589
|
|||||
|
|
THR362
4.927
MET363
4.186
PHE699
3.837
LEU702
3.532
THR703
3.495
GLY704
4.861
PHE736
4.812
ASN740
3.390
LEU743
3.509
LEU744
3.565
PHE747
3.828
|
|||||
| Ligand Name: Cholesterol | Ligand Info | |||||
| Structure Description | Human L-type voltage-gated calcium channel Cav1.3 at 3.0 Angstrom resolution | PDB:7UHG | ||||
| Method | Electron microscopy | Resolution | 3.00 Å | Mutation | No | [1] |
| PDB Sequence |
SIVEWKPFDI
130 FILLAIFANC140 VALAIYIPFP150 EDDSNSTNHN160 LEKVEYAFLI170 IFTVETFLKI 180 IYVRNGWNLL200 DFVIVIVGLF210 SVILEQLTDV236 KALRAFRVLR246 PLRLVSGVPS 256 LQVVLNSIIK266 AMVPLLHIAL276 LVLFVIIIYA286 IIGLELFIGK296 MHKTCFFADS 306 DIVAEEDPAP316 CAFSGNGRQC326 TANGTECRSG336 WVGPNGGITN346 FDNFAFAMLT 356 VFQCITMEGW366 TDVLYWMNDA376 MGFELPWVYF386 VSLVIFGSFF396 VLNLVLGVLS 406 GEFSKEREKA416 KARGDFQKLR426 EKQQLEEDLK436 GYLDWITQAE446 DCRAAVKSVT 524 FYWLVIVLVF534 LNTLTISSEH544 YNQPDWLTQI554 QDIANKVLLA564 LFTCEMLVKM 574 YSLGLQAYFV584 SLFNRFDCFV594 VCGGITETIL604 VELEIMSPLG614 ISVFRCVRLL 624 RIFKVTRHWT634 SLSNLVASLL644 NSMKSIASLL654 LLLFLFIIIF664 SLLGMQLFGG 674 KFNFDETQTK684 RSTFDNFPQA694 LLTVFQILTG704 EDWNAVMYDG714 IMAYGGPSSS 724 GMIVCIYFII734 LFICGNYILL744 NVFLAIAVDN754 LADAESLNTA764 QKEEAEEKIR 876 VGCHKLINHH886 IFTNLILVFI896 MLSSAALAAE906 DPIRSHSFRN916 TILGYFDYAF 926 TAIFTVEILL936 KMTTFGNYFN956 LLDMLVVGVS966 LVSFVVKILR984 VLRVLRPLRA 994 INRAKGLKHV1004 VQCVFVAIRT1014 IGNIMIVTTL1024 LQFMFACIGV1034 QLFKGKFYRC 1044 TDEAKSNPEE1054 CRGLFILYKD1064 GDVDSPVVRE1074 RIWQNSDFNF1084 DNVLSAMMAL 1094 FTVSTFEGWP1104 ALLYKAIDSN1114 GENIGPIYNH1124 RVEISIFFII1134 YIIIVAFFMM 1144 NIFVGFVIVT1154 FQEQGEKEYK1164 NCELDKNQRQ1174 CVEYALKARP1184 LRRYIPKNPY 1194 QYKFWYVVNS1204 SPFEYMMFVL1214 IMLNTLCLAM1224 QHYEQSKMFN1234 DAMDILNMVF 1244 TGVFTVEMVL1254 KVIAFKPKGY1264 FSDAWNTFDS1274 LIVIGSIIDV1284 ALSESITFFR 1319 LFRVMRLVKL1329 LSRGEGIRTL1339 LWTFIKSFQA1349 LPYVALLIAM1359 LFFIYAVIGM 1369 QMFGKVAMRD1379 NNQINRNNNF1389 QTFPQAVLLL1399 FRCATGEAWQ1409 EIMLACLPGK 1419 LCDPESDYNP1429 GEEYTCGSNF1439 AIVYFISFYM1449 LCAFLIINLF1459 VAVIMDNFDY 1469 LTRDWSILGP1479 HHLDEFKRIW1489 SEYDPEAKGR1499 IKHLDVVTLL1509 RRIQPPLGFG 1519 KLCPHRVACK1529 RLVAMNMPLN1539 SDGTVMFNAT1549 LFALVRTALK1559 IKTEGNLEQA 1569 NEELRAVIKK1579 IWKKTSMKLL1589
|
|||||
|
|
PHE534
3.815
THR537
4.162
LEU538
3.726
SER541
3.292
SER542
3.880
HIS544
3.582
LEU898
3.634
ALA901
4.761
ALA902
3.732
ALA905
4.349
PHE914
4.434
ARG915
4.036
ILE918
3.773
LEU919
3.993
PHE922
3.647
PHE926
4.003
|
|||||
| Ligand Name: 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine | Ligand Info | |||||
| Structure Description | Human L-type voltage-gated calcium channel Cav1.3 at 3.0 Angstrom resolution | PDB:7UHG | ||||
| Method | Electron microscopy | Resolution | 3.00 Å | Mutation | No | [1] |
| PDB Sequence |
SIVEWKPFDI
130 FILLAIFANC140 VALAIYIPFP150 EDDSNSTNHN160 LEKVEYAFLI170 IFTVETFLKI 180 IYVRNGWNLL200 DFVIVIVGLF210 SVILEQLTDV236 KALRAFRVLR246 PLRLVSGVPS 256 LQVVLNSIIK266 AMVPLLHIAL276 LVLFVIIIYA286 IIGLELFIGK296 MHKTCFFADS 306 DIVAEEDPAP316 CAFSGNGRQC326 TANGTECRSG336 WVGPNGGITN346 FDNFAFAMLT 356 VFQCITMEGW366 TDVLYWMNDA376 MGFELPWVYF386 VSLVIFGSFF396 VLNLVLGVLS 406 GEFSKEREKA416 KARGDFQKLR426 EKQQLEEDLK436 GYLDWITQAE446 DCRAAVKSVT 524 FYWLVIVLVF534 LNTLTISSEH544 YNQPDWLTQI554 QDIANKVLLA564 LFTCEMLVKM 574 YSLGLQAYFV584 SLFNRFDCFV594 VCGGITETIL604 VELEIMSPLG614 ISVFRCVRLL 624 RIFKVTRHWT634 SLSNLVASLL644 NSMKSIASLL654 LLLFLFIIIF664 SLLGMQLFGG 674 KFNFDETQTK684 RSTFDNFPQA694 LLTVFQILTG704 EDWNAVMYDG714 IMAYGGPSSS 724 GMIVCIYFII734 LFICGNYILL744 NVFLAIAVDN754 LADAESLNTA764 QKEEAEEKIR 876 VGCHKLINHH886 IFTNLILVFI896 MLSSAALAAE906 DPIRSHSFRN916 TILGYFDYAF 926 TAIFTVEILL936 KMTTFGNYFN956 LLDMLVVGVS966 LVSFVVKILR984 VLRVLRPLRA 994 INRAKGLKHV1004 VQCVFVAIRT1014 IGNIMIVTTL1024 LQFMFACIGV1034 QLFKGKFYRC 1044 TDEAKSNPEE1054 CRGLFILYKD1064 GDVDSPVVRE1074 RIWQNSDFNF1084 DNVLSAMMAL 1094 FTVSTFEGWP1104 ALLYKAIDSN1114 GENIGPIYNH1124 RVEISIFFII1134 YIIIVAFFMM 1144 NIFVGFVIVT1154 FQEQGEKEYK1164 NCELDKNQRQ1174 CVEYALKARP1184 LRRYIPKNPY 1194 QYKFWYVVNS1204 SPFEYMMFVL1214 IMLNTLCLAM1224 QHYEQSKMFN1234 DAMDILNMVF 1244 TGVFTVEMVL1254 KVIAFKPKGY1264 FSDAWNTFDS1274 LIVIGSIIDV1284 ALSESITFFR 1319 LFRVMRLVKL1329 LSRGEGIRTL1339 LWTFIKSFQA1349 LPYVALLIAM1359 LFFIYAVIGM 1369 QMFGKVAMRD1379 NNQINRNNNF1389 QTFPQAVLLL1399 FRCATGEAWQ1409 EIMLACLPGK 1419 LCDPESDYNP1429 GEEYTCGSNF1439 AIVYFISFYM1449 LCAFLIINLF1459 VAVIMDNFDY 1469 LTRDWSILGP1479 HHLDEFKRIW1489 SEYDPEAKGR1499 IKHLDVVTLL1509 RRIQPPLGFG 1519 KLCPHRVACK1529 RLVAMNMPLN1539 SDGTVMFNAT1549 LFALVRTALK1559 IKTEGNLEQA 1569 NEELRAVIKK1579 IWKKTSMKLL1589
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .3PE or .3PE2 or .3PE3 or :33PE;style chemicals stick;color identity;select .A:379 or .A:380 or .A:383 or .A:387 or .A:1354 or .A:1357 or .A:1358 or .A:1361 or .A:1377 or .A:1385 or .A:1386 or .A:1388 or .A:1391 or .A:1393 or .A:1394 or .A:1396 or .A:1397 or .A:1400 or .A:1458; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
PHE379
3.763
GLU380
4.546
TRP383
3.573
VAL387
3.667
ALA1354
4.168
ILE1357
4.089
ALA1358
4.322
PHE1361
3.904
MET1377
4.869
ARG1385
2.534
|
|||||
| Click to View More Binding Site Information of This Target and Ligand Pair | ||||||
| Ligand Name: Cholesterol hemisuccinate | Ligand Info | |||||
| Structure Description | Human L-type voltage-gated calcium channel Cav1.3 in the presence of cinnarizine at 3.1 Angstrom resolution | PDB:7UHF | ||||
| Method | Electron microscopy | Resolution | 3.10 Å | Mutation | No | [1] |
| PDB Sequence |
SIVEWKPFDI
130 FILLAIFANC140 VALAIYIPFP150 EDDSNSTNHN160 LEKVEYAFLI170 IFTVETFLKI 180 IYVRNGWNLL200 DFVIVIVGLF210 SVILEQLTDV236 KALRAFRVLR246 PLRLVSGVPS 256 LQVVLNSIIK266 AMVPLLHIAL276 LVLFVIIIYA286 IIGLELFIGK296 MHKTCFFADS 306 DIVAEEDPAP316 CAFSGNGRQC326 TANGTECRSG336 WVGPNGGITN346 FDNFAFAMLT 356 VFQCITMEGW366 TDVLYWMNDA376 MGFELPWVYF386 VSLVIFGSFF396 VLNLVLGVLS 406 GEFSKEREKA416 KARGDFQKLR426 EKQQLEEDLK436 GYLDWITQAE446 DCRAAVKSVT 524 FYWLVIVLVF534 LNTLTISSEH544 YNQPDWLTQI554 QDIANKVLLA564 LFTCEMLVKM 574 YSLGLQAYFV584 SLFNRFDCFV594 VCGGITETIL604 VELEIMSPLG614 ISVFRCVRLL 624 RIFKVTRHWT634 SLSNLVASLL644 NSMKSIASLL654 LLLFLFIIIF664 SLLGMQLFGG 674 KFNFDETQTK684 RSTFDNFPQA694 LLTVFQILTG704 EDWNAVMYDG714 IMAYGGPSSS 724 GMIVCIYFII734 LFICGNYILL744 NVFLAIAVDN754 LADAESLNTA764 QKEEAEEKIR 876 VGCHKLINHH886 IFTNLILVFI896 MLSSAALAAE906 DPIRSHSFRN916 TILGYFDYAF 926 TAIFTVEILL936 KMTTFGNYFN956 LLDMLVVGVS966 LVSFVVKILR984 VLRVLRPLRA 994 INRAKGLKHV1004 VQCVFVAIRT1014 IGNIMIVTTL1024 LQFMFACIGV1034 QLFKGKFYRC 1044 TDEAKSNPEE1054 CRGLFILYKD1064 GDVDSPVVRE1074 RIWQNSDFNF1084 DNVLSAMMAL 1094 FTVSTFEGWP1104 ALLYKAIDSN1114 GENIGPIYNH1124 RVEISIFFII1134 YIIIVAFFMM 1144 NIFVGFVIVT1154 FQEQGEKEYK1164 NCELDKNQRQ1174 CVEYALKARP1184 LRRYIPKNPY 1194 QYKFWYVVNS1204 SPFEYMMFVL1214 IMLNTLCLAM1224 QHYEQSKMFN1234 DAMDILNMVF 1244 TGVFTVEMVL1254 KVIAFKPKGY1264 FSDAWNTFDS1274 LIVIGSIIDV1284 ALSESITFFR 1319 LFRVMRLVKL1329 LSRGEGIRTL1339 LWTFIKSFQA1349 LPYVALLIAM1359 LFFIYAVIGM 1369 QMFGKVAMRD1379 NNQINRNNNF1389 QTFPQAVLLL1399 FRCATGEAWQ1409 EIMLACLPGK 1419 LCDPESDYNP1429 GEEYTCGSNF1439 AIVYFISFYM1449 LCAFLIINLF1459 VAVIMDNFDY 1469 LTRDWSILGP1479 HHLDEFKRIW1489 SEYDPEAKGR1499 IKHLDVVTLL1509 RRIQPPLGFG 1519 KLCPHRVACK1529 RLVAMNMPLN1539 SDGTVMFNAT1549 LFALVRTALK1559 IKTEGNLEQA 1569 NEELRAVIKK1579 IWKKTSMKLL1589
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .Y01 or .Y012 or .Y013 or :3Y01;style chemicals stick;color identity;select .A:534 or .A:537 or .A:538 or .A:541 or .A:542 or .A:543 or .A:544 or .A:545 or .A:546 or .A:1027 or .A:1086 or .A:1087 or .A:1088; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
||||||
| References | Top | ||||
|---|---|---|---|---|---|
| REF 1 | Structural basis for pore blockade of human voltage-gated calcium channel Ca(v)1.3 by motion sickness drug cinnarizine. Cell Res. 2022 Oct;32(10):946-948. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.